(redirected from blast cell)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.
Related to blast cell: Auer rod, band cell, blast cell leukemia

CELL. A small room in a prison. See Dungeon.

A Law Dictionary, Adapted to the Constitution and Laws of the United States. By John Bouvier. Published 1856.
References in periodicals archive ?
(16) Although there are emerging technological advances to screen new mutations, we did not recognize in the literature any study correlating the different subtypes of T-ALL and bone marrow blast cells percentage.
Image segmentation is the significant part of acute lymphoblastic leukaemia detection, because based on precise segmentation a classifier will be able to classify the normal and blast cells accurately [34].
INVESTIGATIONS: Complete blood count, bleeding, clotting and prothrombin time were also done particularly for hemorrhagic disorders, Peripheral smear stained with Leishman's stain and any premature blast cells, shape and color of R.B.C., malarial parasite or any abnormalities were examined, G6PD deficiency test: it was also done to find out whether the patient is G6PD deficiency positive or not, Serum iron and serum iron binding capacity: it was also done.
Immunological detection of blast cell sub-populations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies.
The mean percentage of blast cells in the GO/G1 phase in different heparin concentrations at 0 (without heparin), 1, and 2 h are shown in Table 2.
None of these samples contained blast cells. Thirteen samples contained atypical lymphocytes; 7 of those were also flagged by the Atypical Lymph flag.
A diagnosis of T lymphoproliferative disorder would have been made based on these findings, although further complementary immunophenotyping by immunohistochemistry proved the blast cells to be also positive for CD123 which is more restricted to plasmacytoid dendritic cell marker.
Tsuboi et al.23 used WT1 peptide-based immunotherapy, in which anti WT1 vaccinations caused increase in the WT1-specific cytotoxic-T lymphocytes which reduced the leukemic blast cells in patients with leukemia.
Cellerant is also developing a novel antibody drug-conjugate product, CLT030, to treat AML by selectively targeting and killing leukemic stem and blast cells.
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy in which myeloid lineage cells of the bone marrow cease to differentiate appropriately, resulting in a marked increase in the number of circulating immature blast cells. The counts of mature red blood cells, platelets, and normal white blood cells decline, causing fatigue, shortness of breath, bleeding, and increased susceptibility to infection.